Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( EDICT )
Diabetes Obesity and Metabolism2022Vol. 24(5), pp. 899–907
Citations Over TimeTop 10% of 2022 papers
Olga Lavynenko, Muhammad Abdul‐Ghani, Mariam Alatrach, Curtiss Puckett, John M. Adams, Siham Abdelgani, Naim Alkhouri, Curtis Triplitt, Geoffrey D. Clarke, Juan A. Vasquez, Jinqi Li, Eugênio Cersósimo, Amalia Gastaldelli, Ralph A. DeFronzo
Abstract
At EOS, subjects with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis versus conventional therapy; the severity of hepatic steatosis and fibrosis were both strongly and inversely correlated with insulin resistance; and changes in liver fibrosis scores (APRI, NFS, Fibrosis-4, and AST/ALT ratio) have limited value in predicting response to therapy.
Related Papers
- → Safety and tolerability of pioglitazone(2000)41 cited
- → A once-monthly GLP-1 receptor agonist for treatment of diabetic cats(2019)20 cited
- → Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication(2019)2 cited
- → Don’t dismiss pioglitazone on basis of uncertain risk(2016)
- Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis(2007)